Ming‐Lung Yu, Chung‐Feng Huang, Jee‐Fu Huang, Ning‐Chia Chang, Jeng‐Fu Yang, Zu‐Yau Lin, Shinn‐Cherng Chen, Ming‐Yuh Hsieh, Liang‐Yen Wang, Wen‐Yu Chang, Yi‐Ning Li, Mei‐Shin Wu, Chia‐Yen Dai, Suh‐Hang Hank Juo, Wan‐Long Chuang – 10 September 2010 – Genome‐wide association studies have linked single nucleotide polymorphisms (SNPs) near the interleukin‐28B gene to the hepatitis C virus genotype 1 (HCV‐1) response to peginterferon/ribavirin treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV‐2 patients.

Sepideh Akhavan, Christophe Ronsin, Syria Laperche, Vincent Thibault – 10 September 2010

Zheng Zhang, Shuye Zhang, Zhengsheng Zou, Jianfei Shi, Juanjuan Zhao, Rong Fan, Enqiang Qin, Baosen Li, Zhiwei Li, Xiangsheng Xu, Junliang Fu, Jiyuan Zhang, Bin Gao, Zhigang Tian, Fu‐Sheng Wang – 10 September 2010 – Natural killer (NK) cells are abundant in the liver and serve as a major innate immune component against microbial infection. Although NK cells have been implicated in inducing hepatocellular damage in patients with chronic hepatitis virus infections, the roles that hepatic NK cells play in chronic hepatitis B virus (HBV) infections remain obscure.

Young Hee Shin, Justin Sangwook Ko, Mi Sook Gwak, Gaab Soo Kim, Jong Hwan Lee, Suk‐Koo Lee – 9 September 2010 – We evaluated the value of the stroke volume variation (SVV) calculated with the Vigileo monitor, which recently has been increasingly advocated for fluid management, as a predictor of fluid responsiveness during the anhepatic phase of liver transplantation (LT). We also compared SVV to the central venous pressure (CVP) and pulmonary arterial occlusion pressure (PAOP) in patients. Thirty‐three adult recipients scheduled for elective living donor LT were enrolled in this study.

David Mutimer – 9 September 2010

Ganesh Gunasekaran, Kalman Bencsath, Vera Hupertz, John J. Fung, Gosta Pettersson, Charles Miller – 7 September 2010 – Liver transplantation is the treatment of choice for many liver diseases in the pediatric population. Complications involving late suprahepatic vena cava obstructions after liver transplantation are not common, but they tend to be more frequently seen in pediatric recipients. When such complications have occurred, approaches involving direct abdominal surgery or interventional radiology guidance have been used with satisfactory results.

María Úbeda, Leticia Muñoz, María‐José Borrero, David Díaz, Rubén Francés, Jorge Monserrat, Margaret Lario, Lourdes Lledó, José Such, Melchor Álvarez‐Mon, Agustín Albillos – 7 September 2010 – Systemic activation of the inflammatory immune system contributes to the progression of cirrhosis with ascites. Immune cells become activated after interacting at the mesenteric lymph nodes (MLNs) with bacteria translocated from the gut, and thereafter reach the bloodstream through recirculation.

Sadahisa Okamoto, Rolf Hörnsten, Konen Obayashi, Priyantha Wijayatunga, Ole B. Suhr – 7 September 2010 – In patients with familial amyloidotic polyneuropathy (FAP), heart complications are prognostic factors for mortality and morbidity after liver transplantation (LT). However, only a few studies have analyzed the development of arrhythmia in transplant patients with FAP. We investigated the development of arrhythmia requiring pacemaker insertion (PMI) in Swedish transplant patients with FAP, and we related the findings to gender, age at disease onset, and survival.

Sandro Rossi, Valentina Ravetta, Laura Rosa, Giorgia Ghittoni, Francesca Torello Viera, Francesco Garbagnati, Enrico Maria Silini, Paolo Dionigi, Fabrizio Calliada, Pietro Quaretti, Carmine Tinelli – 7 September 2010 – In most patients with cirrhosis, successful percutaneous ablation or surgical resection of hepatocellular carcinoma (HCC) is followed by recurrence. Radiofrequency ablation (RFA) has proven effective for treating HCC nodules, but its repeatability in managing recurrences and the impact of this approach on survival has not been evaluated.

Yinghua Tian, Rolf Graf, Ashraf Mohammad El‐Badry, Mickaël Lesurtel, Katarzyna Furrer, Wolfgang Moritz, Pierre‐Alain Clavien – 7 September 2010 – The implantation of grafts below 30% of the normal liver volume is associated with a high risk of failure known as small‐for‐size (SFS) syndrome. Strategies to rescue small grafts may have a dramatic impact on organ shortage. Serotonin is a potent growth factor for the liver. The goal of this study was to determine whether enhanced serotonin signaling could prevent the deleterious effects of SFS syndrome.